GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: A meta-analysis

Reproductive BioMedicine Online

Volumn 13, Issue 5, 2006, Pages 628-638

  Griesinger, Georg ^a   Diedrich, K ^a   Tarlatzis, B C ^b   Kolibianakis, E M ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Cetrorelix; Ganirelix; GnRH antagonist; Ovarian hyperstimulation syndrome; Polycystic ovary syndrome; Poor response

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; CUMULUS OOPHORUS; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FERTILIZATION IN VITRO; HUMAN; INCIDENCE; META ANALYSIS; MULTIPLE DRUG DOSE; OBSERVATIONAL STUDY; OOCYTE; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

EID: 33751116124     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60652-9     Document Type: Article

References (55)

1. Aboulghar M, Al-Inany H 2005 Use of GnRHa to induce ovulation in GnRH antagonist cycles. Reproductive BioMedicine Online 11, 520.
2. Akman MA, Erden, HF, Tosun, SB et al. 2001 Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Human Reproduction 16, 868-870.
3. Al-Inany H, Aboulghar M 2002 GnRH antagonist in assisted reproduction: a Cochrane review. Human Reproduction 17, 874-885.
4. Ashrafi M, Mohammadzadeh A, Ezabadi Z, Baghestani AR 2005 A comparative study of GnRH-ant and GnRH-ag protocols in IVF-ICSI in PCOD patients. Iranian Journal of Reproductive Medicine 3, 14-18.
5. Babayof R, Margalioth EJ, Huleihel M et al. 2006 Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRHa compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Human Reproduction Jan26 [Epub ahead of print].
6. Babayof R, Huleihel M, Margalioth EJ et al. 2005 Serum inhibin A and VEGF levels after triggering oocyte maturation with GnRHa (GnRH-a) versus hCG among women with polycystic ovary syndrome (PCOS) undergoing IVF treatment. Human Reproduction 20 (Suppl.1), 298.
7. Bahçeci M, Ulug U, Ben-Shlomo I et al. 2005 Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of Reproductive Medicine 50, 84-90.
8. Bankowski B, Bracero N, King J et al. 2004 Triggering ovulation with leuprolide acetate is associated with lower pregnancy rates. Abstracts of the 19th annual meeting of the ESHRE, Berlin, Germany, P-295, i103.
9. Bar-Hava I, Rabinson J, Ben-Mordechay R et al. 2003 Preventing OHSS by inducing oocyte maturation with GnRHa, instead of hCG, in high responders treated with GnRH antagonist protocols for IVF: a comparison between single dose (3mg) and daily dose (0.25mg) regimens. Abstracts of the Annual meeting of the ESHRE, Madrid, Spain, 2003, xviii 132 (P-389).
10. Bracero NJ, Jurema MW, Posada MN et al. 2001 Triggering ovulation with leuprolide acetate (LA) instead of human chorionic gonadotrophin (hCG) after the use of ganirelix for invitro-fertilization-embryo transfer (IVF-ET) does not compromise cycle outcome and may prevent ovarian hyperstimulation syndrome. Fertility and Sterility (suppl.), S93 (O-254).
11. Bukulmez O, Rehman KS, Langley M et al. 2005 Triggering ovulation by GnRHa leuprolide acetate does not adversely affect the number and quality of the oocytes as compared with recombinant hCG in oocyte donation cycles. Fertility and Sterility 84 (Suppl. 1), S314 (P-455).
12. Carone D, Vizziello GM, Schonauer LM, D'Amato G 2005 Safety and efficacy of GnRHa to trigger ovulation in controlled ovarian hyperstimulation for ART with recombinant FSH and GnRH antagonist in high responders (PCOD) patients. Abstract book of the 8th International Symposium on GnRH-analogues in Cancer and Human Reproduction, Salzburg, Austria, A24.
13. Cheung LP, Lam, PM, Lok, IH et al. 2005 GnRH antagonist versus long GnRHa protocol in poor responders undergoing IVF: a randomized controlled trial. Human Reproduction 20, 616-621
14. Chun E 2005 Severe OHSS can be prevented in GnRH antagonist protocol using GnRHa to trigger ovulation. Fertility and Sterility 84 (Suppl. 1), S301 (P-149).
15. Craft I, Gorgy A, Hill J et al. 1999 Will GnRH-antprovide new hope for patients considered 'difficult responders' to GnRHa protocols? Human Reproduction 14, 2959-2962.
16. De Placido G, Mollo A, Clarizia R et al. 2006 Gonadotrophin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone versus a standard GnRHa short protocol in patients at risk for poor ovarian response. Fertility and Sterility 85, 247-250.
17. Diedrich K, Diedrich C, Santos E et al. 1994 Suppression of the endogenous LH-surge by the LH-RH antagonist cetrorelix during ovarian stimulation. Human Reproduction 9, 788-791.
18. Engel JB, Griesinger G, Schultze-Mosgau A et al. 2006 GnRHas and antagonists in assisted reproduction: pregnancy rate. Reproductive BioMedicine Online 13, 84-87.
19. Engmann L, Hartnett J, Siano L et al. 2005a The Use of GnRHa to trigger final stages of oocyte maturation in patients with polycystic ovarian syndrome (PCOS) and high responders during IVF treatment. Fertility and Sterility 83 (Suppl. 2), S26 (P-40).
20. Engmann L, Diluigi A, Schmidt D et al. 2005b Prevention of ovarian hyperstimulation syndrome (OHSS) with the use of gonadotrophin releasing hormone (GnRH) agonist to trigger final oocyte maturation after co-treatment with GnRH antagonist in patients with polycystic ovarian syndrome (PCOS) or previous high response undergoing IVF treatment - a prospective randomized clinical trial. Fertility and Sterility 84 (Suppl. 1), S96 (O-233).
21. Erden HF, Akman MA, Çiray N, Bahçeci M 2005 The results of fresh and frozen thaw embryo transfer cycles of PCOS patients in which GnRH-antwere used together with GnRHa for LH surge. Fertility and Sterility 84 (Suppl. 1), S164 (P-36).
22. Fauser BC, Devroey P 2005 Why is the clinical acceptance of gonadotrophin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertility and Sterility 83, 1607-1611.
23. Fauser BC, de Jong D, Olivennes F et al. 2002 Endocrine profiles after triggering of final oocyte maturation with GnRHa after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. Journal Clinical Endocrinology and Metabolism 87, 709-715.
24. Felberbaum RE, Diedrich K 2003 Gonadotrophin-releasing hormone antagonists: will they replace the agonists? Reproductive BioMedicine Online 6, 43-53.
25. Felberbaum RE, Reissmann T, Kupker W et al. 1995 Preserved pituitary response under ovarian stimulation with HMG and GnRH-ant (Cetroreliz) in women with tubal infertility. European Journal of Obstetrics, Gynecology and Reproductive Biology 61, 151-155.
26. Golan A, Ron-El R, Herman A 1989 Ovarian hyperstimulation syndrome: an update review. Obstetrical and Gynecological Survey 44, 430-440.
27. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM 2006 GnRHa for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: systematic review and meta-analysis. Human Reproduction Update 12, 159.
28. Griesinger G, Felberbaum R, Diedrich K 2005 GnRH-antin ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry. Human Reproduction 20, 2373-2375.
29. Hohmann FP, Macklon NS, Fauser BC 2003 A randomized comparison of two ovarian stimulation protocols with gonadotrophin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRHa protocol. Journal of Clinical Endocrinology and Metabolism 88, 166-173.
30. Humaidan P, Ejdrup Bredkjaer H, Bungum L et al. 2005 GnRHa (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Human Reproduction 20, 1213-1220.
31. Hwang JL, Seow KM, Lin YH et al. 2004 Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction 19, 1993-2000.
32. Itskovitz J, Boldes R, Levron J et al. 1991 Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropbin-releasing hormone agonist. Fertility and Sterility 56, 213-220.
33. Itskovitz-Eldor J, Kol S, Mannaerts B 2000 Use of a single bolus of GnRH-antagonist triptorelin to trigger ovulation after GnRH-antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: a preliminary report. Human Reproduction 15, 1965-1968.
34. Kim CH, Lee YJ, Hong SH et al. 2004 Efficacy of a GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF-ET. Human Reproduction 19, 105-109.
35. Kol S 2003 Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent! Human Reproduction 18, 1557-1558.
36. Kol S, Itskovitz-Eldor J 2000 Severe OHSS: yes, there is a strategy to prevent it! Human Reproduction 15, 2266-2267.
37. Kol S, Muchtar M 2005 Recombinant gonadotropbin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further research. Reproductive BioMedicine Online 10, 575-577.
38. Kolibianakis EM, Collins J, Tarlatzis B et al. 2006 Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Human Reproduction Update August 18 [Epub ahead of print, doi:10.1093/humupd/dm1038].
39. Kolibianakis E, Schultze-Mosgau A, Schroer A et al. 2005 A lower ongoing pregnancy rate can be expected when GnRHa is used for triggering final oocyte maturation instead of hCG, in patients undergoing IVF with GnRH antagonists. Human Reproduction 20, 2887-2892.
40. Kolibianakis E, Zikopoulos K, Albano C et al. 2003 Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH-antand recombinant FSH for IVF/ICSI. Reproductive BioMedicine Online 7, 313-318.
41. Körösi T, Boga P, Barta C et al. 2006 Use of GnRHa instead of hCG to trigger ovulation in GnRH antagonist IVF/ICSI cycles. Gynecological Endocrinology 22 (Suppl.1), 181 (P20).
42. Ludwig M, Katalinic A, Banz C et al. 2002 Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Human Reproduction 17, 2842-2845.
43. Malmusi S, La Marca A, Giulini S et al. 2005 Comparison of a gonadotrophin-releasing hormone (GnRH) antagonist and GnRH flare-up regimen in poor responders undergoing ovarian stimulation. Fertility and Sterility 84, 402-406.
44. Marci R, Caserta D, Dolo V et al. 2005 GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reproductive BioMedicine Online 11, 189-193.
45. Martínez F, Coroleu B, Marqués L et al. 2003 Comparación del 'Protocolo Corto' versus 'Antagonistas' con o sin Citrato de Clomifeno para estimulación en FIV de pacientes con 'baja respuesta' Revista Iberoamericana de Fertilidad 2025-360.
46. Meltzer S, Girsh E, Shults A, Katz N, Zohav E, Tur-Kaspa I 2002 Prevention of ovarian byperstimulation syndrome in high responders undergoing IVF treatment with GnRH antagonist combined with single dose of GnRHa, instead of HCG, for the induction of oocyte maturation. Abstracts of the 18th Annual Meeting of the ESHRE, Vienna, Austria, O-258, p. 89
47. Mollo A, Clarizia R, Strina I et al. 2005 GnRH antagonist plus hCG versus GnRHa short protocol in patients at risk for poor ovarian response. Human Reproduction 20 (Suppl.1), i126 (P-348).
48. Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J 2003 Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotrophin-releasing hormone agonist versus human chorionic gonadotrophin. Fertility and Sterility 79, 1123-1128.
49. Olivennes F, Fanchin R, Bouchard P et al. 1995. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Human Reproduction 10, 1382-1386.
50. Orvieto R 2005 Can we eliminate severe ovarian hyperstimulation syndrome? Human Reproduction 20, 320-322.
51. Schmidt DW, Bremner T, Orris JJ et al. 2005 A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. Fertility and Sterility 83, 1568-1571.
52. Shapiro BS, Daneshmand ST, Garner FC et al. 2005 Eliminating severe ovarian hyperstimulation syndrome by using GnRHa instead of hCG. Fertility and Sterility 78 (Suppl. 1), S17 (P-12)
53. Tarlatzis B, Fauser BC, Kolibianakis EM et al. 2006 GnRH-antin ovarian stimulation for IVF. Human Reproduction Update, in press.
54. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J 2003 Clinical management of low ovarian response to stimulation for IVF: a systematic review. Human Reproduction Update 9, 61-76.
55. Yding Andersen C, Humaidan P 2005 Characteristics of follicular fluid from women receiving either buserelin or hCG to induce ovulation. Human Reproduction Supplement 1 (20), 65.